Red Propolis Supplementation as a Strategy in Chronic Kidney Disease
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Red Propolis, Placebo Control.
- Who it may be relevant to
- Registry conditions: Kidney Disease, Oxidative Stress, Chronic Kidney Disease, Inflammation. Basic parameters: 18 years — 65 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Brazil
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Red Propolis as a Strategy to Modulate Inflammation and Oxidative Stress in Patients With Chronic Kidney Disease
Overview
The objective of this study is to evaluate the effects of red propolis on inflammation and oxidative stress in patients with chronic kidney disease on conservative management.
Detailed description
Chronic kidney disease (CKD) is associated with chronic systemic inflammation and oxidative stress, which contribute to disease progression and adverse outcomes. Red propolis is a natural substance rich in bioactive compounds with potential anti-inflammatory and antioxidant effects. Clinical evidence on its use in CKD patients is limited, and no studies have evaluated its impact on gene expression related to inflammation and oxidative stress. This randomized, double-blind, placebo-controlled trial will assess the effects of alcoholic extract of red propolis (200 mg/day for 8 weeks) on inflammatory and oxidative stress markers in patients with CKD stages 3-5 under conservative management. Blood samples will be collected at baseline and after intervention to evaluate routine biochemical parameters, inflammatory and oxidative stress markers, and gene expression. Nutritional status and dietary intake will also be assessed.
Interventions
- Dietary supplement Red Propolis
Participants will receive 200mg of red propolis capsules per day for two months. - Other Placebo Control
Participants will receive 200mg of placebo capsules per day for two months.
Primary outcome measures
- Change in inflammatory biomarkers [Time frame: 8 weeks]
Eligibility criteria
Inclusion criteria
- patients with CKD stages 3-5 under conservative management
Exclusion criteria
- pregnant,
- lactating,
- smoker
- patients using antibiotics and antioxidant supplements in the last three months
- patients with autoimmune and infectious diseases,
- patients with cancer, liver disease, and AIDS
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Quadruple blind
- Primary purpose
- Health services research
Study locations
Brazil · 1 center
- Denise Mafra — Rio de Janeiro
Identifiers
NCT: NCT07597005 · DeniseMafra23